Associated Papers
ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.
Yarunin A et al.
Expert Review of Molecular Diagnostics, 2025
Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.
Chaki M et al.
Breast Cancer Research : Bcr, 2025
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.
Borkar S et al.
Cancers, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Goldberg J et al.
Cancer Research Communications, 2024
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Iwata H et al.
Japanese Journal of Clinical Oncology, 2023
Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis.
Najim O et al.
Frontiers in Oncology, 2023
Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer.
Torrisi R et al.
Scientific Reports, 2022
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z et al.
Cancer Research, 2022
Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM et al.
Advances in Experimental Medicine and Biology, 2022
Fusion Genes in Breast Cancer.
Kim J et al.
Advances in Experimental Medicine and Biology, 2021
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.
Mateo L et al.
Genome Medicine, 2020
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.
Pleasance E et al.
Nature Cancer, 2020
Quantitative Evaluation of the Transcriptional Activity of Steroid Hormone Receptor Mutants and Variants Using a Single Vector With Two Reporters and a Receptor Expression Cassette.
Ji H et al.
Frontiers in Endocrinology, 2020
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Froyen G et al.
Cancers, 2019
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
O'Leary B et al.
Clinical Chemistry, 2019
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
Gaillard SL et al.
Gynecologic Oncology, 2019
Dynamics Insights Into the Gain of Flexibility by Helix-12 in ESR1 as a Mechanism of Resistance to Drugs in Breast Cancer Cell Lines.
Khan A et al.
Frontiers in Molecular Biosciences, 2019
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
Pejerrey SM et al.
Hormones & Cancer, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis.
Zhang K et al.
Cancer Management and Research, 2018
Are We Ready to Use ESR1 Mutations in Clinical Practice?
Jeselsohn R
Breast Care (basel, Switzerland), 2017
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Jeselsohn R et al.
Current Oncology Reports, 2017
ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
Angus L et al.
Cancer Treatment Reviews, 2017
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z et al.
International Journal of Molecular Sciences, 2016
Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?
Tabarestani S et al.
Iranian Journal of Cancer Prevention, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Spoerke JM et al.
Nature Communications, 2016
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R et al.
Nature Reviews. Clinical Oncology, 2015
Estrogen receptor mutations and their role in breast cancer progression.
Alluri PG et al.
Breast Cancer Research : Bcr, 2014
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W et al.
Nature Genetics, 2013